Ivacaftor (62) is a potentiator (it enhances the chloride transport) of the cystic fibrosis transmembrane conductance regulator (CFTR), and it is the first drug to be licensed for use that treats an underlying cause of cystic fibrosis [43]. The gene discussed is CFTR; the disease is cystic fibrosis.